Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.
J Thorac Oncol., Sep;7(9):1361-8 (2012)
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
Clin Lung Cancer., Sep;13(5):391-5 (2012)
Beyond bevacizumab: antiangiogenic agents.
Clin Lung Cancer., Sep;13(5):326-33 (2012)
Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab.
Lung Cancer., Jun;76(3):410-5 (2012)
Phase III clinical trial development: a process of chutes and ladders.
Clin. Cancer Res., Nov;16(22):5381-9 (2010)
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.
Med. Oncol., Dec;28 Suppl 1:S152-61 (2011)
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
J. Clin. Oncol., Feb;28(6):949-54 (2010)
Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy.
Oncologist., Nov;14(11):1106-15 (2009)
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.
J. Clin. Oncol., Dec;27(35):6006-11 (2009)
A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
J Thorac Oncol., Jun;4(6):722-7 (2009)
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Clin Lung Cancer., Mar;10 Suppl 1:S7-16 (2009)
Angiogenesis in the treatment of non-small cell lung cancer.
Proc Am Thorac Soc., Apr;6(2):206-17 (2009)
Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy.
Clin Lung Cancer., Jan;10(1):20-7 (2009)
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Clin. Cancer Res., Mar;15(6):2158-65 (2009)
Steps and time to process clinical trials at the Cancer Therapy Evaluation Program.
J. Clin. Oncol., Apr;27(11):1761-6 (2009)
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
J. Clin. Oncol., Mar;27(9):1405-12 (2009)
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
J. Clin. Oncol., Nov;26(33):5407-15 (2008)
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.
Invest New Drugs., Feb;27(1):75-81 (2009)
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naÃ¯ve advanced non-small cell lung cancer.
J Thorac Oncol., Jul;3(7):728-34 (2008)
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
Clin. Cancer Res., Jul;14(14):4517-25 (2008)